Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer

Mlnoru Yoshida, Kentaro Watanabe, Hldeki Tanaka, Syoji Senju, Tsuneo Ishibashi, Masahiro Takamoto, Kotaro Olzumi, Yumiko Kondo, Hlromichi Shigematsu, Takayoshi Ohno, Yoichiro Ichikawa, Nobuyuki Hara, Takashi Mitsuyama, Yoichi Nakanishi, Hozumi Yamada, Shigetaka Kuroki, Akira Motohiro, Hitoshi Ueda, Takuo Kusano, Masafumi HiratsukaYoshihiko Nikaido, Masamitsu Kido, Tomoko Mlyahara, Klyoshi Nlnomiya, Yoshikazu Matsuzaki, Nobuyoshi Mlyazaki, Yukito Ichinose, Tokujiro Yano, Elji Tarai, Takashi Inoue, Hlroshi Aso, Hironori Takihara, Fumihiko Maeda, Kazuyuki Higuchi, Masato Kato, Sadanori Takeo, Yukio Kurita, Atsushi Yano, Yoshiyuki Matsumoto, O. E. Toshiyuki, Tomokazu Zaizen, Koji Namba, Hiroaki Naoe

Research output: Contribution to journalArticle

Abstract

Imipenem/cilastatin sodium (IPM/CS) was administered to 102 patients with respiratory tract infections and lung cancer. Patients with other serious diseases were excluded and a total of 73 patients were enrolled. They were divided into 12 patients who underwent surgery (operated group) and 61 who did not (non-operated group); the latter group included 28 patients treated with anticancer agents or radiation therapy (treated group) and 33 untreated patients (untreated group). IPM/CS was effective in 75% of the patients, both with and without surgery. The drug was effective in 81% of the treated group, although many of the patients had Stage III or more advanced cancer, as well as bronchial occlusion. IPM/CS was also effective in 69% of the untreated group, although many of the patients have serious infections and a PS (Performance Status) of 3 or greater. Thus, IPM/CS treatment achieved good results. Bacteriological studies showed that 3 out of 4 strains in the operated group and 16 out of 18 in the non-operated group were eliminated. Safety was evaluated in all patients. Two patients (2%) experienced side effects and two others (2%) showed abnormal clinical findings, but the symptoms were mild and resolved after discontinuation or completion of therapy. In conclusion, IPM/CS was very effective for treating respiratory infections in patients with lung cancer.

Original languageEnglish
Pages (from-to)36-38
Number of pages3
JournalJapanese Journal of Antibiotics
Volume50
Issue number1
Publication statusPublished - 1997

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Yoshida, M., Watanabe, K., Tanaka, H., Senju, S., Ishibashi, T., Takamoto, M., Olzumi, K., Kondo, Y., Shigematsu, H., Ohno, T., Ichikawa, Y., Hara, N., Mitsuyama, T., Nakanishi, Y., Yamada, H., Kuroki, S., Motohiro, A., Ueda, H., Kusano, T., ... Naoe, H. (1997). Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer. Japanese Journal of Antibiotics, 50(1), 36-38.